Shares of Johnson & Johnson (JNJ) were in the spotlight on Friday morning after the company announced positive results from ...

1 Gooderham, M.J. et al. Phase 3 results from an innovative trial design of treating plaque psoriasis involving difficult-to-treat, high-impact sites with icotrokinra, a targeted oral peptide that ...

Research led by the SKiN Center for Dermatology observed substantial clearance of scalp and body psoriasis and rapid itch ...

Johnson & Johnson (JNJ) posts promising late-stage trial data for plaque psoriasis icotrokinra developed with Protagonist ...

(Reuters) -Johnson & Johnson said on Friday its experimental psoriasis drug helped patients achieve clear or almost clear ...

Arcutis Biotherapeutics (ARQT) announced that the Journal of American Medical Association Dermatology published the results from a pivotal Phase 3 study evaluating the efficacy and safety of ZORYVE ...

Once-daily roflumilast foam significantly improves scalp and body psoriasis in 8 weeks and was well-tolerated in adolescents ...

Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible reset ...

Q1 2025 net product revenue for ZORYVE ® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible ...

On the FDA’s docket this month are two expansion bids, one for GSK’s asthma drug Nucala into COPD and another for Merck’s ...